LPL Financial’s VistaGen Therapeutics VTGN Stock Holding History

LPL Financial’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,067	Closed	-$3.3K	–	4598
2022 Q4	$3.3K	Hold	1,067	–	–	﹤0.01%	4444
2022 Q3	$5K	Hold	1,067	–	–	﹤0.01%	4395
2022 Q2	$28K	Hold	1,067	–	–	﹤0.01%	4307
2022 Q1	$40K	Buy	+1,067	New	+$46.5K	﹤0.01%	4077
2021 Q4	–	Sell	-1,114	Closed	-$92K	–	4462
2021 Q3	$92K	Buy	1,114 +114	+11%	+$9.91K	﹤0.01%	4163
2021 Q2	$95K	Sell	1,000 -333	-25%	-$24.7K	﹤0.01%	4071
2021 Q1	$85K	Buy	1,333 +500	+60%	+$33.4K	﹤0.01%	3949
2020 Q4	$49K	Sell	833 -834	-50%	-$21.3K	﹤0.01%	3732
2020 Q3	$35K	Buy	1,667 +334	+25%	+$6.91K	﹤0.01%	3467
2020 Q2	$21K	Hold	1,333	–	–	﹤0.01%	3412
2020 Q1	$18K	Buy	1,333 +500	+60%	+$9.16K	﹤0.01%	3151
2019 Q4	$17K	Sell	833 -1,250	-60%	-$31.6K	﹤0.01%	3316
2019 Q3	$67K	Buy	2,083 +833	+67%	+$18.6K	﹤0.01%	3187
2019 Q2	$27K	Buy	+1,250	New	+$33.2K	﹤0.01%	3234

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

LPL Financial's VTGN Position: Q1 2023 in Review

LPL Financial sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 1,067 shares — an estimated $3.3K sold.

LPL Financial first reported a position in VTGN in Q2 2019 and held it in 14 quarters. The position peaked at $95K in Q2 2021. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

LPL Financial reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
LPL Financial sold 1,067 VistaGen Therapeutics shares in Q1 2023, an estimated $3.3K.
LPL Financial first reported a position in VistaGen Therapeutics in Q2 2019 and held it in 14 quarters.
LPL Financial's VistaGen Therapeutics position peaked at $95K in Q2 2021.
83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on LPL Financial's 13F filing for Q1 2023, filed 10 May 2023.